Rahima Jamal

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà et al. · New England Journal of Medicine · 2018 · 1.9K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

Bertrand Routy, John Lenehan, Wilson H. Miller et al. · Nature Medicine · 2023 · 451 citations

Life Sciences, Immunology, Oncology +16

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank et al. · JAMA Oncology · 2020 · 436 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 389 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà et al. · Journal of Clinical Oncology · 2020 · 281 citations · Full text

Medicine, Oncology, Pharmacotherapy +17